Curi Bio, a leading developer of human stem cell-based platforms for drug discovery, announced today it has raised $6 million in a Series A financing round. The round, led by Dynamk Capital, is expected to close with additional investors by the end of Q2 2021. The investment will be used to scale its existing business and accelerate the development of new innovative human stem cell platforms, including its MantarrayTM platform. With this financing round, Curi Bio is welcoming Dr. Gustavo Mahler, Managing Partner at Dynamk Capital, as a new board member.

Curi Bio's preclinical discovery platform combines human stem cells, systems, and data to accelerate the discovery of new medicines. The Curi Engine is a seamless, bioengineered platform that integrates human iPSC-derived cell models, tissue-specific biosystems, and A.I./M.L.-enabled phenotypic screening data. Curi's suite of human stem cell-based products and services enable scientists to build more mature and predictive human iPSC-derived tissues-with a focus on cardiac, musculoskeletal, and neuromuscular models-for the discovery, safety testing, and efficacy testing of new drugs in development. The company's proprietary technologies are supported by over 100 publications and 19 patents and continues to grow. By offering drug developers an integrated preclinical platform comprising highly predictive human stem cell models to generate clinically-relevant data, Curi is closing the gap between preclinical data and human results, accelerating the discovery and development of safer, more effective medicines.